the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
October 31, 2018 – The American Food and Drug Administration (FDA) Â recently approved Cemiplimab-Rwlc (Libtayo) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for …
August 14, 2018 – The American Food and Drug Administration (FDA) just approved Patisiran (Onpattro) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. This is the first FDA-approved treatment for …
Patisiran (Onpattro): First targeted RNA-based therapy approved to treat hATTR Read more »
November 24, 2017 – New research indicates that one-size treatment for one form of blood cancer likely does not fit all, particularly when it comes to ethnic differences of patients. Â Thus, African-American men are three times more likely to be …
Cancer is not like cancer: Ethnic background matters Read more »
August 18, 2017 – B-cell precursor acute lymphoblastic leukemia (ALL) is a aggressive and rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell. In the United States, …
Besponsa: Is this really a viable new treatment for ALL? Read more »
September 19, 2016 – This post presents below a virtually unedited announcement by the American Food & Drug Administration (FDA) concerning Duchenne Muscular Dystrophy (DMD) therapy  option which gives much hope for at least some of the affected patients. However, be …
Eteplirsen (Exondys 51) for Duchenne Muscular Dystrophy (DMD) approved Read more »
June 29, 2016 – The saga goes on: The American  Food & Drug Administration (FDA) just approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) infection both with and without cirrhosis (advanced liver disease). For patients with …
May 18, 2016 –  Over the last two years, biologics  targeting the PD-1/PD-L1 pathway (proteins found on the body’s immune cells and some cancer cells), notably Nivolumab (Opdivo) and Pembrolizumab (Keytruda), have come to the clinic for the treatment of a selection of …
Hope for patients with urothelial carcinoma: Atezolizumab (Tecentriq) approved Read more »
April 12, 2016 – The American Food and Drug Administration (FDA) just approved Venetoclax (Venclexta) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with a …
July 13, 2015 – This post persents a press announcement by the U.S. Food and Drug Administration (FDA). The text has slightly been edited by the autor of this blog. Thus, FDA today approved Gefinitib (Iressa) for the first-line treatment …
March 22, 2015 – This post addresses a topic which often gets lost in the current hype on targeted and precision (theragenomic) medicine. The issue is that targeted therapies are not only very precise and highly effective (in most patients) …
Theragenomic Medicine: Targeted Therapies and Associated Toxicity Read more »